Arsenic is a naturally occurring element widely distributed in the earth’s crust. In the environment, arsenic is combined with oxygen, chlorine, and sulfur to form inorganic arsenic compounds. Arsenic in animals and plants combines with carbon and hydrogen to form organic arsenic compounds.
Breathing high levels of inorganic arsenic can give you a sore throat or irritated lungs.
Ingesting very high levels of arsenic can result in death. Exposure to lower levels can cause nausea and vomiting, decreased production of red and white blood cells, abnormal heart rhythm, damage to blood vessels, and a sensation of “pins and needles” in hands and feet.
Ingesting or breathing low levels of inorganic arsenic for a long time can cause a darkening of the skin and the appearance of small “corns” or “warts” on the palms, soles, and torso.
Researchers have found a new oncogenic signaling pathway by which the environmental toxin arsenic may lead to adverse health effects, including bladder cancer. These study results are published in Cancer Research, a journal of the American Association for Cancer Research.
Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.
Where does it come from? Scientists in Arizona are reporting a surprising answer to that question, which has puzzled and perplexed generations of men and women confronted with layers of dust on furniture and floors. Most of indoor dust comes from outdoors. Their report appears in the ACS' Environmental Science & Technology, a semi-monthly journal.
A University of Adelaide forensic pathologist has sounded a worldwide warning of the potential lethal dangers of herbal medicines if taken in large quantities, injected, or combined with prescription drugs.
Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company.
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled “Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents” with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company’s proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value.
The journal Homeopathy (http://www.elsevier.com/locate/homp) has published a two part special issue focusing on biological models of homeopathy. The special issue highlights experiments on homeopathic treatments in biological models, ranging from whole animals and plants to cell cultures and enzymes, showing a remarkable range of findings.
As many as one in 90 children are today being diagnosed with autism--and autism research continues to focus almost exclusively on genetics. In its January/February 2010 issue (posted now at: www.emagazine.com), E-The Environmental Magazine looks at another factor that may be driving up autism rates--environmental toxicity.
The carcinogen aristolochic acid, which was found in many prescribed Chinese herbal products including Guan Mu Tong, is associated with an increased risk of urinary tract cancer, according to a new study published online December 21 in the Journal of the National Cancer Institute.
Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].
ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
ZIOPHARM Oncology, Inc. announced the pricing of its previously announced underwritten public offering of 15,484,000 shares of its common stock and warrants to purchase 7,742,000 shares of its common stock at a public offering price of $3.10 per unit.
ZIOPHARM Oncology, Inc. announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-lead managers for the offering.
Cephalon, Inc. today announced that it has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos. 7,132,570 (the "'570 Patent"), 7,297,346 (the "'346 Patent") and RE37,516 (the "'516 Patent") for the Cephalon product NUVIGIL® (armodafinil) Tablets [C-IV].
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
Physicians for Social Responsibility today released a groundbreaking medical report, "Coal's Assault on Human Health," which takes a new look at the devastating impacts of coal on the human body.
Researchers in MIT's Department of Civil and Environmental Engineering believe they have pinpointed a pathway by which arsenic may be contaminating the drinking water in Bangladesh, a phenomenon that has puzzled scientists, world health agencies and the Bangladeshi government for nearly 30 years. The research suggests that human alteration to the landscape, the construction of villages with ponds, and the adoption of irrigated agriculture are responsible for the current pattern of arsenic concentration underground.
CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.
ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.